Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Delphine Rea, MD, PhD, Gabriel Etienne, MD, Franck Emmanuel Nicolini, MD, PhD, Pascale Cony-Makhoul, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD, Francoise Huguet, MD, Michel Tulliez, MD, Martine Gardembas, MD, Krimo Bouabdallah, MD, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, PhD, Herve Dombret, MD, PhD, François-Xavier Mahon, MD, PhD

Blood (2009) 114 (22): 3288.

https://doi.org/10.1182/blood.V114.22.3288.3288

Published: 2009

Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Blood (2008) 112 (11): 183.

https://doi.org/10.1182/blood.V112.11.183.183

Published: 2008

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Claude Preudhomme, MD, PhD, Catherine Roche-Lestienne, MD/PHD, Antoine Crinquette, MD, Christophe Roumier, MD/PHD, Virginie Eclache, MD, Joëlle Guilhot, MD, Francois Guilhot, MD/PHD, François-Xavier Mahon, MD/PHD

Blood (2006) 108 (11): 2150.

https://doi.org/10.1182/blood.V108.11.2150.2150

Published: 2006

Journal Articles

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

Catherine Roche-Lestienne, MD, PhD, François-Xavier Mahon, MD/PHD, Antoine Crinquette, MD, Joëlle Guilhot, PhD, Francois Guilhot, MD/PHD, Claude Preudhomme, MD/PHD

Blood (2006) 108 (11): 2151.

https://doi.org/10.1182/blood.V108.11.2151.2151

Published: 2006

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

Journal Articles

Bim-EL, Is Sensitive to Proteasome Degradation and Contributes to Inducing Apoptosis after In Vitro Imatinib Mesylate Treatment of BCR-ABL Positive Cells.

Francis Belloc, PhD, Catherine Boyer, Francis Lacombe, MD, PhD, Vincent Praloran, MD, François-Xavier Mahon, MD, PhD

Blood (2004) 104 (11): 4676.

https://doi.org/10.1182/blood.V104.11.4676.4676

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

First Overall Molecular Response of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Bim-EL, Is Sensitive to Proteasome Degradation and Contributes to Inducing Apoptosis after In Vitro Imatinib Mesylate Treatment of BCR-ABL Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only